Share this article
Share this article
MENLO PARK, Calif., May 13, 2021 /PRNewswire/ LIPAC Oncology LLC., a pharmaceutical company utilizing its liposome-bound nano-technology platform to provide precision targeted cancer drugs for the treatment of multiple tumor types, today announced the appointment of Daniel K. Spiegelman as an independent board advisor. We are excited to welcome Dan as an advisor, said Will Robberts, President of LIPAC Oncology. With more than 30 years of biotechnology industry experience and proven expertise in finance, business development and value creation for clinical and commercial stage companies, we look forward to his insights as we advance our oncology pipeline.
Thursday, May 13, 2021
In
Apple v. Qualcomm, Federal Circuit Finds No Standing to Challenge Validity of a Few Patents When Many Were Licensed
The development timeline for small-molecule drugs and biologics is lengthy, estimated to take between 10 and 15 years. As a result, pharmaceutical companies need to consider freedom to operate issues long before they receive FDA approval or market their new product. These considerations might lead a company to take a license, seek to invalidate a competitor’s patent, or some combination of the two. The Patent Trial and Appeal Board (“PTAB”) is a popular venue for challenging patent validity and in 2020, Bio/Pharma and Chemical Patents accounted for 12% of petitions filed at the PTAB.
Global Personalized Cancer Vaccines Market
Global Personalized Cancer Vaccines Market research report has been prepared with a nice combination of industry insight, smart solutions, practical solutions and newest technology to give better user experience. Under market segmentation chapter, research and analysis is done based on several market and industry segments such as application, vertical, deployment model, end user, and geography. To perform this market research study, competent and advanced tools and techniques have been utilized that include SWOT analysis and Porter’s Five Forces Analysis. Businesses can surely anticipate the reduced risk and failure with the winning research report.
Global Personalized Cancer Vaccines Market By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Cervical Cancer, Glioblastoma), By Mechanism of action Type (Tumor-associated antigens (TAAs), Tumor-specific antigens (TSAs), Somatic Mutations in Cancer Pharm
Share this article
Share this article
ResearchAndMarkets.com s offering.
Amid the COVID-19 crisis, the global market for Recombinant DNA Technology estimated at US$609.8 Million in the year 2020, is projected to reach a revised size of US$841.3 Million by 2027, growing at a CAGR of 4.7% over the period 2020-2027.
Medical, one of the segments analyzed in the report, is projected to record 5.2% CAGR and reach US$631.4 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Medical segment is readjusted to a revised 3.4% CAGR for the next 7-year period.
In
Apple v. Qualcomm, Federal Circuit Finds No Standing to Challenge Validity of a Few Patents When Many Were Licensed
The development timeline for small-molecule drugs and biologics is lengthy, estimated to take between 10 and 15 years. As a result, pharmaceutical companies need to consider freedom to operate issues long before they receive FDA approval or market their new product. These considerations might lead a company to take a license, seek to invalidate a competitor’s patent, or some combination of the two. The Patent Trial and Appeal Board (“PTAB”) is a popular venue for challenging patent validity and in 2020, Bio/Pharma and Chemical Patents accounted for 12% of petitions filed at the PTAB.